Insights

Could this be the large cap version of the Brainchip (ASX:BRN) share price? 

Could Pro Medicus Ltd (ASX: PME) be a large cap version of the Brainchip (ASX: BRN) share price? We take a closer look at both companies.
The post Could this be the large cap version of the Brainchip (ASX:BRN) share price?  appeared first on Motley Fool Australia. –

woman holdings small pile of coins representing brainchip share price and larger pile of coins

The Brainchip Holdings Ltd (ASX: BRN) share price ascended to unicorn status after running more than 200% since August and 1000% this year. However, with its underwhelming finances and arguable short-term share price top, should investors be looking at Pro Medicus Limited (ASX: PME) as a more reliable, large cap player in the software and AI for healthcare space? 

What does Pro Medicus do? 

Pro Medicus is a leading provider of radiology information systems (RIS), picture archiving and communication systems (PACS) and advanced visualisation solutions to help clients deliver first-rate patient care by enhancing and streamlining medical practice management. The company generates revenue from a range of offerings including software as a service (SaaS), professional services and support services. In FY20, its revenues increased 23.9% to $56.8 million, NPAT increased 20.7% to $23.1 million and cash reserves were up 34.3% to $43.4 million. The company is debt free and even looks to pay a full year dividend of 12 cents or a yield of 0.50%. 

Wasn’t Pro Medicus also a unicorn? 

Pro Medicus was a market darling unicorn at some stage, having gone from a mere microcap to its inclusion into the S&P/ASX 200 Index (ASX: XJO). The company boasts a $2.7 billion market capitalisation with increasing profitability to catch up to its high valuation. 

How does Pro Medicus compare to the Brainchip share price? 

Brainchip is now worth more than $700 million thanks to its recent price run. The company is still very much in its research and development and prototype stage with its proprietary neuromorphic processor called Akida. This processor would analyse data within itself rather than transferring to the cloud or a data centre. The solution would be high-performance, small, ultra-low power and would have a range of cutting edge capabilities. In Brainchip’s half-year financial report, it reported US$13,397 in revenue and an operating loss of US$6.19 million. More recently, the company entered into an agreement to support a Phase I NASA program for a processor that meets spaceflight requirements. The agreement cited that payments are intended to offset the company’s expenses to support partner needs.

From a revenue perspective, Pro Medicus generates a few hundred times more revenue than Brainchip despite only being worth four times more from a market capitalisation perspective. While Brainchip’s technology could have significant applications across many sectors, the company has yet to generate any meaningful revenues or sales. Furthermore, it could be at risk of a potential capital raising should money in the bank dry up. 

Foolish takeaway

Pro Medicus represents a large cap version of Brainchip with a proven product and growing revenues. I believe Brainchip is in a volatile position where much of its hype has been priced in. For those interested in the space, Pro Medicus could be an alternative. 

Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now

When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*

In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.

Find out the names of our 3 Post COVID Stocks – For FREE!

*Returns as of 6/8/2020

More reading

Lina Lim has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. recommends Pro Medicus Ltd. The Motley Fool Australia owns shares of and has recommended Pro Medicus Ltd. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The post Could this be the large cap version of the Brainchip (ASX:BRN) share price?  appeared first on Motley Fool Australia.

Trade The World Anywhere & Anytime!

Mobile app platform with over 50,000 global listed securities across 12 markets (over 70% global market capitalisation), right from your Android or iOS device.

Integrated with exclusive trading idea and investment analysis tools to help you find actionable insight on virtually every financial instrument across our 12 global markets, to help you optimise your trading strategies.

Refer Your Friends

Tell your friends about Monex and gift them FREE access to our trading tools.

We respect your privacy and will only send this one email notification to your friends. 

Share With Your Friends

Share on facebook
Share on twitter
Share on linkedin

Monex Trading Tools Access and Usage Terms

The Monex Trading Tools (referred to as ‘tools’ hereafter) are available to you inside your client portal;


To activate access to the tools, you must have a verified and approved trading account and have made a deposit of at least AUD $1000.


An active and funded account with a positive trading balance is required to continue to have access to the tools;


Although the tools are available to you indefinitely, Monex Securities may at it’s discretion disable access to the tools in the future;


Monex securities reserves the right to change these terms and conditions from time to time, as it sees fit, without notice.

Important Notice
iOS & Android App - 12 International Markets & Over 70% Global Market Cap. $0 Brokerage On US Trades. Click Here!